Search tips
Search criteria 


Logo of brheartjLink to Publisher's site
Br Heart J. 1980 September; 44(3): 254–258.
PMCID: PMC482394

Haemodynamic changes induced by prostacyclin in man.


Intra-arterial or intravenous infusion of prostacyclin at three dose levels (2, 5, and 10 ng/kg per min) in 10 subjects without evidence of coronary heart disease or cardiac failure, led to a distinct fall in peripheral and total pulmonary vascular resistances. This was accompanied by a drop in intra-arterial blood pressure, and the acceleration of heart rate. Stroke volume, cardiac output, mean right atrial pressure, and left ventricular end-diastolic pressure showed no significant changes. Except for sporadic headache no side effects occurred. Prostacyclin appears to act predominantly on resistance vessels. The haemodynamic effects produced by prostacyclin in man might be of clinical interest in the treatment of conditions associated with a significant rise in vascular resistance.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (649K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Gryglewski RJ, Bunting S, Moncada S, Flower RJ, Vane JR. Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins. 1976 Nov;12(5):685–713. [PubMed]
  • Moncada S, Gryglewski RJ, Bunting S, Vane JR. A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins. 1976 Nov;12(5):715–737. [PubMed]
  • Gryglewski RJ, Korbut R, Ocetkiewicz A. Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature. 1978 Jun 29;273(5665):765–767. [PubMed]
  • Gryglewski RJ, Szczeklik A. Inhibition of prostacyclin formation by lipid peroxides in the arterial wall: hypothetical step in development of atherosclerosis. Mater Med Pol. 1978 Oct-Dec;10(4):338–341. [PubMed]
  • Szczeklik A, Nizankowski R, Skawinski S, Szczeklik J, Gluszko P, Gryglewski RJ. Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet. 1979 May 26;1(8126):1111–1114. [PubMed]
  • Weissler AM, Harris WS, Schoenfeld CD. Systolic time intervals in heart failure in man. Circulation. 1968 Feb;37(2):149–159. [PubMed]
  • Parmley WW, Diamond G, Tomoda H, Forrester JS, Swan HJ. Clinical evaluation of left ventricular pressures in myocardial infarction. Circulation. 1972 Feb;45(2):358–366. [PubMed]
  • Szczeklik A, Gryglewski RJ, Nizankowski R, Musiał J, Pietoń R, Mruk J. Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men. Pharmacol Res Commun. 1978 Jun;10(6):545–556. [PubMed]
  • Leffler CW, Hessler JR. Pulmonary and systemic vascular effects of exogenous prostaglandin I2 in fetal lambs. Eur J Pharmacol. 1979 Feb 15;54(1-2):37–42. [PubMed]
  • Fitzpatrick TM, Alter I, Corey EJ, Ramwell PW, Rose JC, Kot PA. Cardiovascular responses to PGI2 (prostacyclin) in the dog. Circ Res. 1978 Feb;42(2):192–194. [PubMed]
  • Szczeklik J, Dubiel JS, Mysik M, Pyzik Z, Krol R, Horzela T. Effects of prostaglandin E1 on pulmonary circulation in patients with pulmonary hypertension. Br Heart J. 1978 Dec;40(12):1397–1401. [PMC free article] [PubMed]
  • Olsson AG, Carlson LA. Clinical, hemodynamic and metabolic effects of intraarterial infusions of prostaglandin E1 in patients with peripheral vascular disease. Adv Prostaglandin Thromboxane Res. 1976;1:429–432. [PubMed]
  • Kadowitz PJ, Chapnick BM, Feigen LP, Hyman AL, Nelson PK, Spannhake EW. Pulmonary and systemic vasodilator effects of the newly discovered prostaglandin, PGI2. J Appl Physiol Respir Environ Exerc Physiol. 1978 Sep;45(3):408–413. [PubMed]
  • Nowak J. Prostaglandins in the cardiovascular system in man. A biochemical and physiological study. Acta Physiol Scand Suppl. 1979;467:1–49. [PubMed]
  • Massie BM, Chatterjee K. Vasodilator therapy of pump failure complicating acute myocardial infarction. Med Clin North Am. 1979 Jan;63(1):25–51. [PubMed]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group